MedImmune FluMist Manufacturing Violations Cited In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA also issued a “complete response” letter for MedImmune’s sBLA for the vaccine in younger children as a result of the compliance issues.